FGFR Signaling Inhibition and Multidrug Resistance: Lessons from Infigratinib (BGJ 398) and PD 173074

Study Background and Research Question

Resistance to chemotherapy remains a formidable barrier in oncology, with multidrug resistance (MDR) often driven by ATP-binding cassette (ABC) transporters such as P-glycoprotein (ABCB1). These efflux pumps reduce intracellular drug accumulation, limiting the efficacy of microtubule-targeting agents like paclitaxel (PTX) and doxorubicin (Dox). While inhibitors of fibroblast growth factor receptors (FGFRs) are under investigation for their role in tumor biology, their impact on MDR mechanisms is not fully resolved. The study by Boichuk et al. addresses whether pan-FGFR inhibition can overcome ABCB1-mediated chemoresistance and how this compares to more selective FGFR1/VEGFR2 inhibitors such as PD 173074 (paper).

Key Innovation from the Reference Study

This research demonstrates, for the first time, that infigratinib (BGJ 398)—a potent pan-FGFR1-4 inhibitor—can restore chemosensitivity in ABCB1-overexpressing cancer cell lines by directly impairing ABCB1-mediated drug efflux. The study provides mechanistic evidence that BGJ 398 enhances the intracellular retention and cytotoxicity of chemotherapeutics in MDR cells, in contrast to the selective FGFR1/VEGFR2 inhibitor PD 173074, which does not modulate ABCB1 activity or chemosensitivity (paper).

Methods and Experimental Design Insights

Boichuk et al. employed a combination of in vitro models, focusing on triple-negative breast cancer (TNBC) and gastrointestinal stromal tumor (GIST) cell lines with established MDR phenotypes (ABCB1 overexpression). Cells were treated with BGJ 398, PD 173074, and chemotherapeutic agents (PTX, Dox), both individually and in combination. Key methodologies included:

• Cell viability and proliferation assays following drug treatments.
• Apoptosis quantification via cleaved PARP and caspase-3 detection, and Annexin V staining.
• Immunoblotting for phosphorylated (activated) FGFR, FRS2, and downstream effectors (STAT1/3, S6).
• Efflux assays using fluorescently labeled chemotherapeutics (Flutax-2, doxorubicin) and Calcein AM to monitor ABCB1 transport activity.

The design enabled head-to-head comparison of BGJ 398 and PD 173074 for both FGFR pathway inhibition and MDR modulation.

Core Findings and Why They Matter

1. BGJ 398 Restores Chemosensitivity via ABCB1 Inhibition
In ABCB1-overexpressing cancer cells, BGJ 398 synergistically increased apoptosis when combined with PTX or Dox, as evidenced by elevated levels of cleaved PARP, caspase-3, and Annexin V-positive cells (paper). BGJ 398 alone did not induce significant apoptosis, underscoring its chemosensitizing rather than cytotoxic role in this context. 2. Mechanistic Dissection: Efflux Blockade without ABCB1 Downregulation
BGJ 398 did not alter ABCB1 protein expression but significantly impaired the efflux of fluorescent chemotherapeutics and Calcein AM, confirming functional inhibition of ABCB1. This suggests that BGJ 398 directly interacts with ABCB1 or its transport activity, rather than altering its abundance. 3. FGFR Pathway Inhibition Confirmed by Both BGJ 398 and PD 173074
Both FGFR inhibitors reduced phosphorylation of FGFR, FRS2, and downstream effectors, confirming robust pathway inhibition (paper). This finding aligns with established literature on PD 173074's nanomolar potency for FGFR1/VEGFR2 inhibition (source: workflow_recommendation). 4. PD 173074 Does Not Reverse MDR via ABCB1
Unlike BGJ 398, PD 173074 failed to retain chemotherapeutic agents inside ABCB1-overexpressing cells and did not sensitize these cells to PTX or Dox. Thus, while both compounds inhibit FGFR signaling and can suppress tumor cell proliferation (source: internal_article), only BGJ 398 directly impacts ABCB1-mediated drug resistance (paper).

Comparison with Existing Internal Articles

Recent internal reviews highlight PD 173074 as a benchmark FGFR1/VEGFR2 inhibitor for dissecting angiogenesis and tumor biology, with high selectivity and low off-target activity (source: workflow_recommendation; internal_article). However, these resources emphasize its application in FGFR signaling pathway inhibition, cell proliferation, and angiogenesis assays, rather than MDR reversal. The current reference study clarifies that PD 173074's lack of ABCB1-modulatory activity limits its utility for overcoming transporter-mediated resistance, setting it apart from pan-FGFR inhibitors like BGJ 398.

Limitations and Transferability

The findings are based on in vitro cell line models with high ABCB1 expression; in vivo relevance and clinical translation require further investigation. Additionally, the ability of pan-FGFR inhibitors to block ABCB1-mediated efflux may not generalize to all tumor types or ABC transporter subfamilies. PD 173074 remains an optimal tool for selective FGFR1/VEGFR2 pathway inhibition, but should not be presumed effective for direct MDR reversal without supporting evidence (paper).

Protocol Parameters

• FGFR1 kinase inhibition | ~21.5 nM (IC50) | cell-based & biochemical assays | enables robust pathway suppression | product_spec
• VEGFR2 autophosphorylation inhibition | 100–200 nM (IC50) | angiogenesis/cell signaling models | allows selective anti-angiogenic studies | product_spec
• Cell culture studies | 10–100 nM | proliferation/FGFR signaling | standard for in vitro FGFR1/VEGFR2 pathway interrogation | workflow_recommendation
• Reversal of ABCB1-mediated MDR | not supported for PD 173074 | MDR cancer models | lacks functional efflux inhibition in tested systems | paper
• Animal dosing | 1–2 mg/kg IP or 3–30 mg/kg PO | murine tumor models | well-tolerated for pathway inhibition | product_spec

Research Support Resources

Researchers engaged in FGFR signaling pathway inhibition, angiogenesis inhibition, or cancer research requiring highly selective tools can utilize PD 173074 (SKU A8253) for robust and reproducible results in cell and animal models. While PD 173074 does not inhibit ABCB1-mediated drug efflux, its nanomolar potency and selectivity make it a reference-standard FGFR1/VEGFR2 inhibitor for dissecting pathway-specific mechanisms (source: internal_article). For workflows exploring MDR reversal, broader-spectrum FGFR inhibitors such as BGJ 398 may be considered as outlined in the reference study (paper).